The relation between parameters from homeostasis model assessment and glycemic control in type 2 diabetes

Journal of the Medical Association of Thailand

Volumn 90, Issue 11, 2007, Pages 2284-2290

  Dansuntornwong, Bantita ^a   Chanprasertyothin, Suwannee ^a   Jongjaroenprasert, Wallaya ^a   Ngarmukos, Chardpraon ^a   Bunnag, Pongamorn ^a   Puavilai, Gobchai ^a   Ongphiphadhanakul, Boonsong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Glycemic control; Homeostasis model assessment (HOMA); T2DM

Indexed keywords

ACARBOSE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CELL FUNCTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; GLYCEMIC CONTROL; HEALTH CARE UTILIZATION; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT CODING; RATING SCALE; SENSITIVITY AND SPECIFICITY;

BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH STATUS INDICATORS; HEMOGLOBIN A, GLYCOSYLATED; HEMOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PILOT PROJECTS; SICKNESS IMPACT PROFILE;

EID: 37149046764     PISSN: 01252208     EISSN: 01252208     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. American Diabetes Association. Clinical Practice Recommendations 2005 Diabetes Care 2005; 28 (Suppl 1): S1-79.
2. The perspective of the Diabetes Control and Complications Trial. The absence of a glycemic threshold for the development of long-term complications. Diabetes 1996; 45: 1289-98.
3. Skyler JS. Diabetic complications. The importance of glucose control. Endocrinol Metab Clin North Am 1996; 25: 243-54.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
5. Groop L, Schalin C, Franssila-Kallunki A, Widen E, Ekstrand A, Eriksson J. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989; 87: 183-90.
6. Bonora E, Targher G, Alberiche M, Formentini G, Calcaterra F, Lombardi S, et al. Predictors of insulin sensitivity in Type 2 diabetes mellitus. Diabet Med 2002; 19: 535-42.
7. Karter AJ, D'Agostino RB, Jr., Mayer-Davis EJ, Wagenknecht LE, Hanley AJ, Hamman RF, et al. Abdominal obesity predicts declining insulin sensitivity in non-obese normoglycaemics: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Obes Metab 2005; 7: 230-8.
8. Farin HM, Abbasi F, Reaven GM. Body mass index and waist circumference correlate to the same degree with insulin-mediated glucose uptake. Metabolism 2005; 54: 1323-8.
9. Ostgren CJ, Lindblad U, Ranstam J, Melander A, Rastam L. Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project. Diabet Med 2002; 19: 125-9.
10. Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med 2005; 165: 1395-400.
11. Levy JC, Matthews DR, Hermans MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 1998; 21: 2191-2.
12. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004; 116: 230-5.
13. Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26: 2238-43.
14. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003; 17: 305-22.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
16. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
17. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997; 20: 1087-92.
18. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
19. Levy JC, Rudenski A, Burnett M, Knight R, Matthews DR, Turner RC. Simple empirical assessment of beta-cell function by a constant infusion of glucose test in normal and type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1991; 34: 488-99.
20. Levy J, Manley S, Sutton P, Camps I. Beta-cell function assessed by the hyperglycemic clamp: reproducibility compared with HOMA analysis from fasting values, and factors influencing variability. Abstract in 55th Annual meeting and scientific sessions of The American Diabetes Association. Atlanta, Georgia, June 10-13, 1995. Abstracts Diabetes 1995; 44(Suppl 1): 89A.
21. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes 1999; 48: 1779-86.
22. Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, Bown EG, et al. Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia 1985; 28: 401-11.
23. Haffner SM, Kennedy E, Gonzalez C, Stern MP, Miettinen H. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 1996; 19: 1138-41.
24. Emoto M, Nishizawa Y, Maekawa K, Hiura Y, Kanda H, Kawagishi T, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas. Diabetes Care 1999; 22: 818-22.
25. U.K. Prospective Diabetes Study Group. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58.
26. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
27. Kumar S, Prange A, Schulze J, Lettis S, Barnett AH. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients. Diabet Med 1998; 15: 772-9.
28. Tan M, Johns D, Gonzalez GG, Antunez O, Fabian G, Flores-Lozano F, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004; 26: 680-93.
29. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001; 12: 413-23.
30. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998; 15: 297-303.
31. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998; 15: 290-6.
32. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362-5.
33. Vague P, Nguyen L. Rationale and methods for the estimation of insulin secretion in a given patient: from research to clinical practice. Diabetes 2002; 51(Suppl 1): S240-S244.
34. Matthews D, Bakst A, Weston W, Hemyari P. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. 35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts Diabetologia 1999; 42(Suppl 1): A228.
35. Tan MH, Glazer NB, Johns D, Widel M, Gilmore KJ. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004; 20: 723-8.
36. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-70.
37. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004; 21: 568-76.
38. Taverna MJ, Pacher N, Bruzzo F, Slama G, Selam JL. Beta-cell function evaluated by HOMA as a predictor of secondary sulphonylurea failure in Type 2 diabetes. Diabet Med 2001; 18: 584-8.